Search company, investor...

Replikun Biotech

Stage

Incubator/Accelerator | Alive

About Replikun Biotech

Replikun Biotech is a immunotherapy company founded in March 2005. The company is focused on the development and commercialization of immunotherapies to combat infectious diseases and cancer. Replikun offers licensing and collaboration opportunities based on KUNrep Vectors, its gene delivery and expression technology. The technology is underpinned by an integrated portfolio of granted and pending patent applications which comprise the KUNrep Vectors, their pharmaceutical applications and methods of manufacture. Replikun Biotech is conducting pre-clinical studies of two products: an investigational oncology candidate and a HIV vaccine, both developed using the KUNrep Vector system.

Headquarters Location

PO Box 126

2138,

Australia

Missing: Replikun Biotech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Replikun Biotech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Replikun Biotech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Replikun Biotech is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Replikun Biotech Frequently Asked Questions (FAQ)

  • What is Replikun Biotech's latest funding round?

    Replikun Biotech's latest funding round is Incubator/Accelerator.

  • Who are the investors of Replikun Biotech?

    Investors of Replikun Biotech include i.lab.

  • Who are Replikun Biotech's competitors?

    Competitors of Replikun Biotech include ChemoCentryx, Hawaii Biotech, Nuclea Biotechnologies, VirxSys, Action Pharma and 13 more.

Compare Replikun Biotech to Competitors

W
Welgen

Welgen, Inc. is a biotech company developing technologies and products for biomedical research. The company was founded in 2002 to develop vectors for gene delivery and silencing that facilitate research activities in both academia and industry. The company's products provide the medical research community and the pharmaceutical industry with rapid and cost-efficient approaches for gene function research and drug development.

Bar Harbor BioTechnology Logo
Bar Harbor BioTechnology

Bar Harbor Biotech is a life sciences company spun-out from The Jackson Laboratory to develop gene expression products and services. Bar Harbor Biotech's technology focuses on real-time quantitative polymerase chain reaction (PCR), an established technique for gene expression used in disease research, molecular diagnostics, drug discovery, and other fields of biology research.

B
Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

O
Orphagenix

OrphageniX is a drug development company aiming to develop therapeutics for genetic diseases using advancements in "Gene Editing" technologies. OrpageniX will focus on the low volume, high margin specialty pharmaceutical niche area of "Orphan Diseases" which are protected under the Orphan Drug Act (ODA). Per the company, the OrphageniX technology can be used for diagnostics and research tools. Gene Editing uses the cell's innate repair mechanisms to repair mutations that result in genetic diseases. According to OrphaageniX, it is similar to gene therapy but avoids the risks associated with a viral vector. It works like anti-sense and RNAi, but is more efficient and permanent within the repaired cell because it changes the gene itself and not the transient message. The company states that it has major collaborations with Yale Medical School, Albert Einstein Medical Center and the University of Washington.

V
Vector Biolabs

Vector Biolabs is a biotechnology company focused on developing robust gene delivery products, by using its technologies. The company's products are to be used in scientific research, target identification and drug development.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.